A new technology for cellular immunotherapy developed by Abramson Cancer Center researchers at Penn Medicine showed promising anti-tumor activity in the lab against hard-to-treat cancers driven by the once-considered “undruggable” KRAS mutation, including lung, colorectal, and pancreatic. The foundational technology is available for licensing through PCI.
![](https://pci.upenn.edu/wp-content/uploads/2021/06/Penn-Medicine-Logo.png)